Welcome to our dedicated page for KalVista Pharmaceuticals SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KalVista Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KalVista Pharmaceuticals's regulatory disclosures and financial reporting.
KalVista Pharmaceuticals’ Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity. On May 22, 2026, she exercised 5,000 Restricted Stock Units (RSUs), each converting into one share of common stock for no cash cost. A Form 4 footnote explains that on May 26, 2026 she sold 1,489 common shares at $26.7778 per share solely to cover tax withholding obligations through a “sell to cover” transaction, which the company notes was not a discretionary sale. After these transactions, she directly holds 59,291 shares of common stock and 40,000 RSUs that continue to vest quarterly, subject to continued service.
KalVista Pharmaceuticals’ Chief Medical Officer, Paul K. Audhya, reported routine equity compensation activity and a related tax sale. On May 22, 2026, he exercised 5,000 Restricted Stock Units, receiving 5,000 shares of common stock for no cash consideration as part of RSU vesting.
On May 26, 2026, he sold 2,239 shares of common stock at $26.7778 per share in a “sell to cover” transaction to satisfy tax withholding obligations, which the filing states was not a discretionary trade. Following these transactions, he directly held 150,260 shares of common stock and 40,000 RSUs.
KalVista Pharmaceuticals’ CEO Benjamin L. Palleiko reported RSU vesting and a related tax sale. On May 21, 2026, 23,250 Restricted Stock Units converted into an equal number of common shares for no cash payment. On May 22, 2026, he sold 10,926 common shares at an average price of $26.7844 per share to cover tax withholding obligations from this RSU vesting, a non-discretionary “sell to cover” transaction. Following these transactions, he directly holds 479,989 common shares and 255,750 RSUs, so the tax-related sale represents a small portion of his overall equity position.
KalVista Pharmaceuticals Chief Commercial Officer Nicole Sweeny reported routine equity compensation activity. On May 21, 2026, 6,250 restricted stock units converted into the same number of shares of common stock at no cost upon vesting. Each RSU represents a right to receive one share.
On May 22, 2026, she sold 1,861 shares of common stock at an average price of $26.7844 per share. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting as a “sell to cover” transaction and was not a discretionary trade. After these transactions, Sweeny directly holds 55,780 shares of KalVista common stock.
KalVista Pharmaceuticals chief development officer Christopher Yea reported routine equity compensation activity. He exercised 3,750 restricted stock units (RSUs), receiving the same number of common shares for no cash cost. Following this, he sold 2,358 common shares at $26.7844 per share.
According to the footnotes, this sale was a non-discretionary “sell to cover” transaction to fund tax withholding tied to the RSU vesting, rather than an elective sale. After these transactions, Yea directly holds 228,759 common shares and 41,250 RSUs that continue to vest quarterly, indicating he retains nearly all of his equity exposure.
KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya reported routine equity compensation-related transactions. On May 21, 2026, he exercised 6,250 restricted stock units (RSUs), receiving 6,250 shares of Common Stock at $0.00 per share upon settlement.
On May 22, 2026, he sold 2,685 Common Stock shares at an average price of $26.7844 per share solely to cover tax withholding obligations through a "sell to cover" transaction, which the filing states was not a discretionary sale. After these transactions, he directly owned 147,499 Common Stock shares and 68,750 RSUs representing contingent rights to receive an equal number of shares over time, subject to vesting.
KalVista Pharmaceuticals Chief Financial Officer Brian Piekos reported routine equity compensation activity and a tax-related share sale. On May 21, 2026, 5,000 restricted stock units converted into 5,000 shares of common stock for no cash consideration. On May 22, 2026, 1,489 of those shares were sold at $26.7844 per share solely to cover tax withholding obligations under a “sell to cover” arrangement, which the company states was not a discretionary transaction. After these events, Piekos directly held 21,661 shares of common stock, and his reported restricted stock unit balance was 55,000 units.
KalVista Pharmaceuticals received an Amendment No. 8 to a Schedule 13D from a group of Frazier Life Sciences funds and related entities updating their ownership information. Frazier Life Sciences Public Fund, L.P. directly holds 1,249,165 shares of KalVista common stock, representing 2.3% of the outstanding shares based on 53,240,888 shares outstanding as of May 7, 2026. Frazier Life Sciences X, L.P. holds 427,983 shares (0.8%), Frazier Life Sciences XI, L.P. holds 145,592 shares (0.3%), and Frazier Life Sciences XII, L.P. holds 6,563 shares (0.0%). The filing clarifies that certain entities act as general partners to these funds and that James N. Topper and Patrick J. Heron share voting and investment power only over the FLS X shares, with other funds managed by investment committees where individual members are not attributed beneficial ownership.
KalVista Pharmaceuticals chief development officer Christopher Yea reported routine equity compensation activity. On May 17, 2026, 1,774 restricted stock units vested and were converted into the same number of common shares for no cash consideration. On May 18, 2026, 1,108 common shares were sold at $26.76 per share solely to cover tax withholding obligations through a “sell to cover” arrangement, described as a non-discretionary transaction. After these transactions, Yea directly holds 227,367 shares of KalVista common stock.
KalVista Pharmaceuticals, Inc. Chief Medical Officer Paul K. Audhya reported routine equity compensation activity involving restricted stock units (RSUs) and a small related sale. On May 17, 2026, he exercised RSUs covering 2,419 shares of common stock at $0.00 per share, converting all of those RSUs into common shares.
On May 18, 2026, he sold 1,032 shares of common stock at an average price of $26.76 per share. A footnote explains this was a "sell to cover" transaction to satisfy tax withholding obligations tied to the RSU vesting, and is described as not a discretionary trade. Following these transactions, he directly holds 143,934 shares of KalVista common stock.